NEW YORK – Blue Earth Therapeutics last week said it has enrolled the first two patients in a Phase II trial of its investigational radiotherapeutic 177Lu-rhPSMA-10.1 in patients with ...

The 177Lu-PSMA-617 treatment allows for more patients to benefit from the treatment. It enables doctors to determine how well a treatment is actually working. Patients have superior disease ...

You have full access to this article via your institution. Hormone therapy represents the standard of care for advanced prostate cancer (PCa), but patients ultimately become refractory and develop ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Clinical Performance and Patient Outcomes Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry ...

Clinical Implications for Salvage Radiation Therapy Contouring Guidelines Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy Is 18F ...

(UroToday.com) The 2025 AUA annual meeting featured an advanced prostate cancer session and a presentation by Dr. Neal Shore discussing health-related quality of life, pain and safety outcomes in the ...

After a median follow-up of 20.9 months, patients on 177Lu-PSMA-617 had radiographic progression-free survival (PFS) of 8.7 months, compared to 3.4 months in the control group, and overall ...

"In an earlier study, we found that patients whose kidney function worsened after lutetium-177 PSMA therapy showed changes in kidney structure ... Decline after 177Lu Prostate-specific Membrane ...

State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing 210003,China ...

PSMA-targeted radioligand therapy with 177Lu-PSMA-617 has been shown to improve survival outcomes in select pre-treated mCRPC patients; however, disease control is typically short-term. PSMA may be ...